| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
03-05-2012, 03:06 PM
|
#1 | |||
|
||||
|
Senior Member
|
Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
Ahmed I et al. – These findings are consistent indicating that increased glutamatergic activity is implicated in the development and maintenance of levodopa–induced dyskinesias. They support the hypothesis that blockade of glutamate transmission may have a place in the management of disabling dyskinesias in Parkinson's disease http://brain.oxfordjournals.org/cont...in.awr028.full
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
|
 Reply With Quote
|
|
03-05-2012, 03:20 PM
|
#2 | ||
|
|||
|
In Remembrance
|
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
|
|
Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Glutamate identified as predictor of disease progression in multiple sclerosis (Topix | Multiple Sclerosis | |||
| Cough suppressant may treat dyskinesias in Parkinson's patients | Parkinson's Disease | |||
Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
Linear Mode
